What if we tolerated diseases?

KNOWABLE The immune cells that fight bacteria and viruses are well-known. But some scientists think we should devote more attention to a second prong of defense: one that allows our bodies to more harmlessly live with pathogens until they’re cleared from our systems.

Read More

MOv18 – opening a new front for immunotherapy

CRUK Parasites, allergy and innovation – the journey to get the first IgE anti-cancer drug into a human was certainly not easy. Here we follow Sophia Karagiannis and James Spicer on an immunological adventure as they work with our Centre for Drug Discovery on this potentially ground-breaking new class of drug.

Read More

Relax to the max

NEW SCIENTIST We are finally getting a grasp of what rest and relaxation actually do to the brain and body. The insights could help us all turbocharge our downtime, finds Liam Drew

Read More

Cannabis for chronic pain: the stand-off

THE PHARMACEUTICAL JOURNAL In the UK, the standing of cannabis as a member of the analgesic pharmacopeia is somewhat nebulous, and there are strong opinions on both sides about whether there is enough evidence for its effectiveness.

Read More

Decoding the business of brain–computer interfaces

NATURE ELECTRONICS Fifty years after the term brain–computer interface was coined, the neurotechnology is being pursued by an array of start-up companies using a variety of different technologies. But the path to clinical and commercial success remains uncertain.

Read More

A new approach to cancer immunotherapy

CRUK Forty years ago, hints of a new component of the immune system caused a stir. As the initial controversy turned into therapeutic promise, the importance of translating this research for the treatment of cancer became very clear. Here, we chart the story of gamma delta T cells from discovery to clinical trials…


Read More